Showing 1691-1700 of 2152 results for "".
- Market Scope: Premium IOLs Expected to Drive Market Growth Over the Next 5 Yearshttps://modernod.com/news/market-scope-premium-iols-expected-to-drive-market-growth-over-the-next-5-years/2477796/The revenue contribution of premium IOLs is expected to grow over the next 5 years as the number and different types of IOL designs offered to cataract and refractive patients seeking better visual outcomes increases, according to a Market Scope report. In 2019, premium IOLs accounted a th
- Market Scope: New Refractive Atlas Identifies Location of LVC Candidates and Refractive Surgeonshttps://modernod.com/news/market-scope-new-refractive-atlas-identifies-location-of-lvc-candidates-and-refractive-surgeons/2477682/The metro areas of New York, Los Angeles, Dallas, and Chicago account for 14 percent of the population age 20 to 44 in the US and 9.3 percent of the US population with refractive error, according to a Market Scope report. However, on a per capita share basis, most of the metro areas in Col
- Fed Unveils Major Expansion of Market Interventionhttps://modernod.com/news/fed-unveils-major-expansion-of-market-intervention/2477439/The Federal Reserve unveiled a major expansion of lending programs Monday that are designed to keep credit markets functioning after they seized up last week, expanding its facilities to include certain types of corporate and municipal debt, according to a Wall Street Journal
- Fact.MR Highlights Accelerating Sales of Corrective Lenses; Contact Lens Market Set to Record 5% Through 2029https://modernod.com/news/fact-mr-highlights-accelerating-sales-of-corrective-lenses-contact-lens-market-set-to-record-5-through-2029/2477317/The proliferation of visually-impaired consumers and their participation in outdoor activities, coupled with increasing cases of myopia, presbyopia, and astigmatism, will drive the global contact lens market to witness a staggering growth trajectory of over 5% between 2019 and 2029, according to
- Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025https://modernod.com/news/expanding-product-needs-surgery-growth-will-drive-retinal-surgical-device-market-to-nearly-2-billion-by-2025/2477308/Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retinal surgical device market is expected to total more than $1.57 billion in 2020, with revenue rising
- Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda Marketing Authorization Application in Europehttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-for-review-of-the-roclanda-marketing-authorization-application-in-europe/2477200/Aerie Pharmaceuticals announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Roclanda is currently marketed as Rocklatan in the United States, where it is
- Leiters and Prodigy Health Enter into National Sales and Marketing Agreementhttps://modernod.com/news/leiters-and-prodigy-health-enter-into-national-sales-and-marketing-agreement/2477157/Leiters and Prodigy Health have entered into a national sales and marketing agreement that will permit Prodigy Health to bring its ProdigyVision technology platform to the Leiters portfolio of 503B compounded sterile preparations in collaboration with the Leiters sal
- Aerie Pharmaceuticals Submits Marketing Authorization Application for Roclanda in Europehttps://modernod.com/news/aerie-pharmaceuticals-submits-marketing-authorization-application-for-roclanda-in-europe/2477139/Aerie Pharmaceuticals announced that it has submitted the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Should the MAA for Roclanda be accepted for review by the EMA, an opinion from t
- Ophthalmic Laser Market Expected to Total $406 Million in 2019https://modernod.com/news/ophthalmic-laser-market-expected-to-total-406-million-in-2019/2477117/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total nearly $406 million in 2019 and grow at a compound annual rate of 1.6 percent from 2019 to 2024, according to Market Scope estimates. Factor
- EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/ema-and-fda-accept-marketing-applications-for-chugais-satralizumab-in-neuromyelitis-optica-spectrum-disorder-nmosd/2477062/Chugai Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab, an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of adult and adolescent patients with neuromyelitis optica spectrum